News and Trends 19 Dec 2025 U.S. vaccine approvals to undergo overhaul: what do the changes mean? A strict new vaccine approval process in the U.S. could dramatically slow things down for biopharma and the public, experts warn. December 19, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jul 2024 Influenza solution deals pile up as pandemic preparedness increases Influenza deals have been piling up in the last few weeks. Discover why that is and how are companies and government preparing for pandemics. July 29, 2024 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 11 Jul 2023 AIS Biotech: startup employs carbohydrates to fight the flu Keen on discovering novel ways to tackle viral infections, AIS Biotech, a French company based in the Alps, aims to combat influenza, more commonly known as the flu, by leveraging the medicinal promise behind glycobiotechnology. A field that has been gaining momentum over the past decade, glycobiotechnology is the study of complex carbohydrates which has […] July 11, 2023 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2023 AI program finds multiple influenza drug targets Poolbeg Pharma, a clinical-stage biopharma company focusing on infectious and other prevalent diseases, has announced a breakthrough in its world-first influenza Artificial Intelligence (AI) Programme working with the company CytoReason. Poolbeg’s disease progression data from influenza human challenge trials combined with CytoReason’s broad repositories of curated disease data were analyzed using CytoReason’s AI-led platform. The […] June 29, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Apr 2023 aVaxziPen’s needle-free vaccine yields positive data across multiple diseases aVaxziPen, a biotech company developing a novel needle-free vaccine delivery platform, presented data at the World Vaccine Congress (WVC) in Washington, U.S., recently. The company presented a poster entitled, “Needle-free, injectable solid dose vaccine delivery generates equivalent immune response with different antigens and animal models.” The company said immunogenicity data from four in vivo models […] April 26, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Feb 2023 AAHI bags $9.9M to develop nasal spray influenza RNA vaccine The Access to Advanced Health Institute (AAHI) has been awarded a project agreement worth up to $9.9 million through the Medical CBRN Defense Consortium (MCDC) Other Transaction Authority (OTA) to develop a prototype intranasal bivalent influenza RNA vaccine candidate. The candidate will be based on AAHI’s self-amplifying RNA (saRNA) platform, which targets both pandemic A(H5N1) […] February 7, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2023 Poolbeg expands POLB 001 into oncology Poolbeg Pharma has announced the strategic expansion of POLB 001 into oncology. POLB 001 is a strain agnostic, small molecule immunomodulator being studied to address the unmet medical need for a treatment for severe influenza. While investigating the role of cytokine release syndrome (CRS) in severe influenza, Poolbeg discovered data specific to the overt immune […] January 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2022 Poolbeg influenza trial successfully completed Poolbeg Pharma has received initial results having completed its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need for severe influenza. The study showed no further clinical activity is required to complete the objectives of the trial, bringing the recruitment […] December 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Startup Scout 21 Nov 2022 Osivax is designing future-proof influenza and Covid vaccines Viruses causing influenza and COVID-19 continually evolve to escape our vaccine protections. The French firm Osivax is developing vaccines that are harder for the viruses to evade. Many life-saving vaccines have been developed and approved to protect against viral infections including COVID-19 and influenza. Commercially available vaccines typically activate the production of antibodies against fragments […] November 21, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2022 Virax Biolabs introduces flu, Covid-19 and RSV rapid test kits Rapid test kits that can accurately identify infections related to respiratory syncytial virus (RSV), influenza and Covid-19 can deliver results in 15 minutes. UK-based Virax Biolabs, a biotech company focused on the prevention, detection and diagnosis of viral diseases announced today (November 3) the distribution of a tripe virus antigen rapid test kit has been […] November 3, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 Patents granted for Poolbeg Pharma influenza and respiratory virus infections treatments Poolbeg Pharma has been granted patents by the US Patent and Trademark Office (USPTO) for POLB 001, a small molecule immunomodulator for the treatment of severe influenza and POLB 002, a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections. POLB 001 The USPTO granted a patent for the majority of Poolbeg’s claims around the […] October 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2022 Pneumagen embarks on phase 2 proof of concept influenza study Biotech company Pneumagen says the first person has been dosed in its phase 2 controlled human infection challenge study. Its product, Neumifil, is an intranasal, broad-spectrum antiviral treatment to prevent or, if infected, reduce and manage, viral respiratory tract infections. The phase 2 trial is a single center, randomized, double-blinded, placebo-controlled study evaluating two dose […] August 16, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email